Latest Period
Q1 2026
Security Snapshot
X4 Pharmaceuticals, Inc - Common Stock (XFOR) Institutional Ownership
CUSIP: 98420X202
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
80
Shares (Excl. Options)
90,401,419
Price
$4.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- XFOR on Nasdaq
- Shares outstanding
- 87,101,353
- Price per share
- $4.10
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 90,401,419
- Total reported value
- $373,355,951
- % of total 13F portfolios
- 0.01%
- Share change
- +3,891,867
- Value change
- +$16,452,686
- Number of holders
- 80
- Price from insider filings
- $4.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- XFOR - X4 Pharmaceuticals, Inc - Common Stock is tracked under CUSIP 98420X202.
- 80 institutions reported positions in Q1 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 75 to 80 between Q4 2025 and Q1 2026.
- Reported value moved from $343,681,474 to $373,355,951.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 80 institutions filings for Q1 2026.
Security key
98420X202
Latest holder period
Q1 2026
13F holders
80
13D/G owners
12
CIK / CUSIP context first
Open Q1 2026 holders
XFOR full holder history
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
X4 Pharmaceuticals, Inc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98420X202:
Significant Owners of X4 Pharmaceuticals, Inc - Common Stock (XFOR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Empery Asset Management, LP | 10% | 0% | $35,180,748 | +$25,462,897 | 9,043,894 | +262% | Empery Asset Management, LP | 31 Dec 2025 |
| MORGAN STANLEY | 10% | +8.9% | $29,940,219 | +$2,318,051 | 8,884,338 | +8.4% | Morgan Stanley | 28 Feb 2026 |
| FMR LLC | 9.7% | $33,996,400 | 8,499,100 | FMR LLC | 31 Oct 2025 | |||
| Saturn V Capital Management LP | 7.4% | $25,026,241 | 6,433,481 | Saturn V Capital Management LP | 24 Oct 2025 | |||
| PERCEPTIVE ADVISORS LLC | 7.6% | $20,980,760 | 6,064,680 | Perceptive Advisors LLC | 27 Oct 2025 | |||
| Trails Edge Capital Partners, LP | 5.8% | -41% | $20,333,894 | +$11,320,168 | 5,227,222 | +126% | Trails Edge Capital Partners, LP | 31 Dec 2025 |
| Growth Equity Opportunities 18 VGE, LLC | 6.2% | -38% | $17,496,802 | +$9,734,867 | 5,057,610 | +125% | Growth Equity Opportunities 18 VGE, LLC | 27 Oct 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 3.9% | -60% | $13,272,653 | +$4,544,819 | 3,411,993 | +52% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Coastlands Capital LP | 10% | 0% | $7,773,911 | +$37,418 | 2,491,638 | +0.48% | Coastlands Capital LP | 03 Oct 2025 |
| Nantahala Capital Management, LLC | 2.8% | -72% | $9,528,431 | +$798,030 | 2,449,468 | +9.1% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| Deep Track Capital, LP | 10% | $4,568,300 | 2,366,995 | Deep Track Capital, LP | 12 Aug 2025 | |||
| BlackRock, Inc. | 3% | $377,954 | 179,125 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 80 institutional investors reported holding 90,401,419 shares of X4 Pharmaceuticals, Inc - Common Stock (XFOR). This represents 104% of the company’s total 87,101,353 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) together control 100% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 11% | 9,466,992 | +15% | 0% | $39,098,676 |
| Empery Asset Management, LP | 10% | 8,944,118 | -0.08% | 44% | $36,939,207 |
| FMR LLC | 9.3% | 8,103,400 | -4.7% | 0% | $33,467,042 |
| Bain Capital Life Sciences Investors, LLC | 9.1% | 7,967,454 | 0% | 3% | $32,905,585 |
| PERCEPTIVE ADVISORS LLC | 7.7% | 6,737,648 | +6.7% | 0.55% | $27,826,486 |
| Saturn V Capital Management LP | 7.4% | 6,456,646 | +11% | 4.8% | $26,665,948 |
| Deep Track Capital, LP | 7.3% | 6,339,535 | +26% | 0.54% | $26,182,280 |
| Kalehua Capital Management LLC | 4.3% | 3,722,840 | 0% | 11% | $15,375,329 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 3,497,612 | 0% | 0% | $14,445,138 |
| BRAIDWELL LP | 3.8% | 3,272,954 | -2.8% | 0.45% | $13,517,300 |
| Rosalind Advisors, Inc. | 3.7% | 3,214,766 | +23% | 5.4% | $13,276,984 |
| Blackstone Inc. | 3.1% | 2,681,922 | 0% | 0.05% | $11,076,338 |
| Trails Edge Capital Partners, LP | 3% | 2,571,478 | 0% | 2.5% | $10,620,204 |
| Nantahala Capital Management, LLC | 2.8% | 2,449,468 | 0% | 0.63% | $10,116,303 |
| BVF INC/IL | 2.6% | 2,233,742 | 0% | 0.29% | $9,225,354 |
| SAMSARA BIOCAPITAL, LLC | 2.1% | 1,832,566 | -6.5% | 0.74% | $7,568,498 |
| BlackRock, Inc. | 1.4% | 1,211,794 | -1.2% | 0% | $5,004,710 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 1,210,514 | +2062% | 0% | $4,999,423 |
| Woodline Partners LP | 1.1% | 1,001,095 | +0.02% | 0.02% | $4,134,522 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 939,726 | -0.08% | 0% | $3,883,286 |
| GOLDMAN SACHS GROUP INC | 1% | 882,134 | +6% | 0% | $3,643,213 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.98% | 856,222 | +3768% | 0% | $3,536,197 |
| STEMPOINT CAPITAL LP | 0.98% | 850,742 | -5.3% | 0.68% | $3,513,564 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 480,733 | 0% | 0% | $1,985,427 |
| STATE STREET CORP | 0.46% | 403,534 | +104% | 0% | $1,666,595 |
Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 90,401,419 | $373,355,951 | +$16,452,686 | $4.13 | 80 |
| 2025 Q4 | 85,919,846 | $343,681,474 | +$228,817,038 | $4.00 | 75 |
| 2025 Q3 | 13,652,105 | $46,690,414 | +$40,048,768 | $3.42 | 40 |
| 2025 Q2 | 2,150,633 | $4,086,190 | +$4,064,925 | $1.90 | 49 |
| 2025 Q1 | 83,045 | $20,007 | +$20,007 | $0.24 | 2 |